KN38-7271: Completed Phase IIa enrollment

KeyNeurotek completed enrollment of 97 patients in a double-blind, placebo-controlled, European Phase IIa trial ( KN38-7271-001) evaluating 2 dose levels of KN38-7271. The compound has Orphan Drug des...